Strengthen your procedures to support the identity, strength, quality, purity and potency of your drug product and drug substances from FDA Team Leader Alfred Del Grosso's Top 10 List of Analytical Inadequacies for IND or BLA Submissions. Gain a thorough understanding of FDA expectations for analytical procedures and validations in this must-attend presentation for those currently working in analytical development/science.
Effectively remove product and process impurities and monitor your product quality by hearing FDA Principal Investigator Mikhail V. Ovanesov present his strategies to control the levels of implicated impurities by changing the manufacturing process. Details on how to properly monitor product quality using relevant lot release assays will also be discussed.
Want to learn more? Download our agenda.
As a reader of this blog, you’ll receive 15% off the standard rate when using code XB13193BLOG to register. If you have questions about the event, contact Kate Devery (Kdevery@iirusa.com), or visit our webpage.
We look forward to seeing you October 21-23 in Washington, D.C!
Cheers,
The WCB Team
Visit our Homepage
Follow us on Twitter
Join our WCB LinkedIn Group
P.S. When you register for Well Characterized Biologicals, you’ll also have access to all sessions for our co-located event, Produce and Process Variants & Impurities conference.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment